BridgeBio Pharma (BBIO) Total Current Liabilities (2018 - 2026)

BridgeBio Pharma has disclosed Total Current Liabilities across 9 years of filings, most recently posting $816.4 million for Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $816.4 million, up 436.72% year-over-year; the trailing twelve-month figure through Mar 2026 was $816.4 million (up 436.72% YoY), and the FY2025 annual result was $288.0 million, up 86.51% from the prior year.
• Total Current Liabilities came in at $816.4 million for Q1 2026 at BridgeBio Pharma, up from $288.0 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $816.4 million in Q1 2026 to a low of $96.6 million in Q1 2023.
• The 5-year median for Total Current Liabilities is $141.2 million (2022), against an average of $185.9 million.
• Across the five-year window, Total Current Liabilities slipped 21.99% in 2023 and surged 436.72% in 2026, its largest moves.
• BridgeBio Pharma's Total Current Liabilities stood at $121.4 million in 2022, then climbed by 18.46% to $143.8 million in 2023, then gained by 7.34% to $154.4 million in 2024, then surged by 86.51% to $288.0 million in 2025, then jumped by 183.49% to $816.4 million in 2026.
• The last three Total Current Liabilities figures came in at $816.4 million (Q1 2026), $288.0 million (Q4 2025), and $216.6 million (Q3 2025), per Business Quant data.